145 related articles for article (PubMed ID: 32201860)
1. A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease.
Bennett A; Evers Carlini L; Duley C; Garrett A; Annis K; Wagnon J; Dalal R; Scoville E; Beaulieu D; Schwartz D; Horst S
Crohns Colitis 360; 2020 Jan; 2(1):otaa013. PubMed ID: 32201860
[TBL] [Abstract][Full Text] [Related]
2. Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn's Disease.
Forss A; Clements M; Myrelid P; Strid H; Söderman C; Wagner A; Andersson D; Hjelm F; ; Olén O; Halfvarson J; Ludvigsson JF
Dig Dis Sci; 2023 Jan; 68(1):65-76. PubMed ID: 35459973
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease.
Ollech JE; Normatov I; Peleg N; Wang J; Patel SA; Rai V; Yi Y; Singer J; Dalal SR; Sakuraba A; Cohen RD; Rubin DT; Pekow J
Clin Gastroenterol Hepatol; 2021 Jan; 19(1):104-110. PubMed ID: 32109634
[TBL] [Abstract][Full Text] [Related]
4. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.
Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
Aliment Pharmacol Ther; 2017 May; 45(9):1232-1243. PubMed ID: 28252210
[TBL] [Abstract][Full Text] [Related]
5. Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.
Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
Inflamm Bowel Dis; 2017 May; 23(5):833-839. PubMed ID: 28328624
[TBL] [Abstract][Full Text] [Related]
6. Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry.
Iborra M; Beltrán B; Fernández-Clotet A; Iglesias-Flores E; Navarro P; Rivero M; Gutiérrez A; Sierra-Ausin M; Mesonero F; Ferreiro-Iglesias R; Hinojosa J; Calvet X; Sicilia B; González-Muñoza C; Antolín B; González-Vivo M; Carbajo AY; García-López S; Martín-Cardona A; Surís G; Martin-Arranz MD; de Francisco R; Cañete F; Domènech E; Nos P;
Aliment Pharmacol Ther; 2020 Sep; 52(6):1017-1030. PubMed ID: 32770851
[TBL] [Abstract][Full Text] [Related]
7. Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn's disease.
Yao J; Peng X; Zhong Y; Su T; Bihi A; Zhao J; Liu T; Wang W; Hu P; Zhang M; Zhi M
Front Med (Lausanne); 2023; 10():1105981. PubMed ID: 37554510
[TBL] [Abstract][Full Text] [Related]
8. Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn's disease (PROSE): a 16-week follow-up.
Forss A; Clements M; Myrelid P; Strid H; Söderman C; Wagner A; Andersson D; Hjelm F; ; Olén O; Ludvigsson JF; Halfvarson J
Scand J Gastroenterol; 2021 Jun; 56(6):680-686. PubMed ID: 33794731
[TBL] [Abstract][Full Text] [Related]
9. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of ustekinumab in patients with refractory Crohn's disease: a multicentre real-life study in Italy.
Scribano ML; Aratari A; Neri B; Bezzio C; Balestrieri P; Baccolini V; Falasco G; Camastra C; Pantanella P; Monterubbianesi R; Tullio A; Saibeni S; Papi C; Biancone L; Cosintino R; Faggiani R
Therap Adv Gastroenterol; 2022; 15():17562848211072412. PubMed ID: 35186121
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response.
Heron V; Li Fraine S; Panaccione N; Restellini S; Germain P; Candido K; Bernstein CN; Bessissow T; Bitton A; Chauhan UK; Lakatos PL; Marshall JK; Michetti P; Seow CH; Rosenfeld G; Panaccione R; Afif W
J Can Assoc Gastroenterol; 2022 Oct; 5(5):208-213. PubMed ID: 36196277
[TBL] [Abstract][Full Text] [Related]
12. Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab.
Harris KA; Horst S; Gadani A; Nohl A; Annis K; Duley C; Beaulieu D; Ghazi L; Schwartz DA
Inflamm Bowel Dis; 2016 Feb; 22(2):397-401. PubMed ID: 26752468
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Safety of Ustekinumab for Moderate to Severely Active Crohn's Disease: Results from an Early Access Program in Brazil.
Chebli JMF; Parra RS; Flores C; Moraes AC; Nones RB; Gomes TNF; Perdomo AMB; Scapini G; Zaltman C
J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362709
[TBL] [Abstract][Full Text] [Related]
14. The Long-Term Clinical Effectiveness of Ustekinumab in Antitumor Necrosis Factor-Experienced Crohn's Disease Patients.
Altuwaijri M; Hakami L; Alharbi O; Almadi M; Alshankiti S; Aljebreen A; Azzam N
Cureus; 2022 Aug; 14(8):e28536. PubMed ID: 36185868
[TBL] [Abstract][Full Text] [Related]
15. Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry.
Iborra M; Beltrán B; Fernández-Clotet A; Gutiérrez A; Antolín B; Huguet JM; De Francisco R; Merino O; Carpio D; García-López S; Mesonero F; Navarro P; Ferreiro-Iglesias R; Carbajo AY; Rivero M; Gisbert JP; Piñero-Pérez MC; Monfort D; Bujanda L; García-Sepulcre MF; Martín-Cardona A; Cañete F; Taxonera C; Domènech E; Nos P;
Aliment Pharmacol Ther; 2019 Aug; 50(3):278-288. PubMed ID: 31222872
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry.
Casas-Deza D; Lamuela-Calvo LJ; Gomollón F; Arbonés-Mainar JM; Caballol B; Gisbert JP; Rivero M; Sánchez-Rodríguez E; Arias García L; Gutiérrez Casbas A; Merino O; Márquez L; Laredo V; Martín-Arranz MD; López Serrano P; Riestra Menéndez S; González-Muñoza C; de Castro Parga L; Calvo Moya M; Fuentes-Valenzuela E; Esteve M; Iborra M; Dura Gil M; Barreiro-De Acosta M; Lorente-Poyatos RH; Manceñido N; Calafat M; Rodríguez-Lago I; Guardiola Capo J; Payeras MA; Morales Alvarado VJ; Tardillo C; Bujanda L; Muñoz-Nuñez JF; Ber Nieto Y; Bermejo F; Almela P; Navarro-Llavat M; Martínez Montiel P; Rodríguez Gutiérrez C; Van Domselaar M; Sesé E; Martínez Pérez T; Ricart E; Chaparro M; García MJ; López-Sanromán A; Sicilia B; Orts B; López-García A; Martín-Arranz E; Pérez-Calle JL; de Francisco R; García-Planella E; Domènech E; García-López YS
J Crohns Colitis; 2023 Jan; 17(1):83-91. PubMed ID: 35913456
[TBL] [Abstract][Full Text] [Related]
17. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
Eberl A; Hallinen T; Af Björkesten CG; Heikkinen M; Hirsi E; Kellokumpu M; Koskinen I; Moilanen V; Nielsen C; Nuutinen H; Suhonen UM; Utriainen K; Vihriälä I; Soini E; Wennerström C; Nissinen R; Borsi A; Koivunen M; Tillonen J; Sipponen T
Scand J Gastroenterol; 2019 Jun; 54(6):718-725. PubMed ID: 31184512
[No Abstract] [Full Text] [Related]
18. Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study.
Biemans VBC; van der Meulen-de Jong AE; van der Woude CJ; Löwenberg M; Dijkstra G; Oldenburg B; de Boer NKH; van der Marel S; Bodelier AGL; Jansen JM; Haans JJL; Theeuwen R; de Jong D; Pierik MJ; Hoentjen F
J Crohns Colitis; 2020 Jan; 14(1):33-45. PubMed ID: 31219157
[TBL] [Abstract][Full Text] [Related]
19. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis.
Meserve J; Ma C; Dulai PS; Jairath V; Singh S
Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2728-2740.e1. PubMed ID: 34628078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
